Bdkrb2 agonist (lobradimil) has either been used or currently in clinical trials for treating brain tumors and HIV-infected individuals with cryptococcal meningitis (ClinicalTrials.gov: NCT00005602, NCT00019422, NCT00001502, and NCT00002316). Here, BDKRB2 is linked to Cryptococcal meningitis.